Cancer 
        Digest        

Men with prostate cancer whose tumors have specific genetic mutations saw a nearly 50 percent reduction in the risk of cancer progression when they received naraparib.

Prostate cancer patients who received shorter, higher-dose course radiation treatment (MHFRT) had the same cancer control rates as those...

Man undergoing PSMA-PET scan – image credit UCLA Health CANCER DIGEST – Jan. 5, 2025 – Nearly half of high-risk prostate cancer patients...

Dr. Charlie Hamm, first author of the study and physician at Charité's Department of Radiology, in front of a magnetic resonance imaging...

Men with prostate cancer who have chosen "watchful waiting" or surveillance might be able to extend the time before more aggressive treatmen

CANCER DIGEST – Nov. 17, 2024 – Researchers at UCLA have found that combining an immunotherapy drug with chemotherapy significantly...

CANCER DIGEST – Oct. 19, 2024 – Using nanotechnology to treat prostate cancer, researchers eliminated tumors in 73 percent of men treated.

CANCER DIGEST – Aug. 24, 2024 – Men with mutations in a certain gene and whose prostate cancer is recurring as judged by a rising PSA,...

Test could significantly reduce unnecessary biopsies CANCER DIGEST – April 20, 2024 – University of Michigan researchers have developed a...

CANCER DIGEST – April 1, 2024 – An MRI of the prostate combined with a PSA test can determine clinically significant prostate cancer,...